Please assess the completion status of the following clinical trial:

Trial Title: PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of metastatic breast cancer~* Previous treatment with anthracyclines and taxanes~* Patients who will start Eribulin or who have already received only the first dose (cycle 1, day 1) of Eribulin according to the approved indication~* Ability to comply with sample collection~* Patient has signed the study Informed Consent Form (ICF) and the specific Pharmacogenetic ICF.~* Absence of any contraindication to treatment~Exclusion Criteria:~* Previous treatment with Eribulin in a previous line of treatment~* Previous treatment with Eribulin off label

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm with Eribulin mesylate (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).